Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)


Iressa for Elderly and/or Poor Performance Status Patients with an EGFR Mutation
Howard (Jack) West, MD

Several years ago, we learned that EGFR tyrosine kinase inhibitors (TKIs) were not a very helpful strategy for an unselected population of frail patients in the US, clearly inferior to standard chemotherapy (see prior posts here and here). This work was in patients who hadn't been tested for molecular markers like EGFR mutations, and our interpretation of the previous US-based trial left us with the conclusion that an EGFR TKI like tarceva (erlotinib) or iressa (gefitinib) was an inferior chemotherapy alternative and apparently ineffective treatment for the majority of patients with a marginal performance status, but it could still be an effective option for patients selected to be especially likely to benefit from this class of agents, like patients with an EGFR mutation.

This was the subject of pure speculation until now. A manuscrupt by Inoue and colleagues (abstract here) has just been published that describes the experience of treating patients with an EGFR mutation and who are either elderly or have a poor performance status or both with an EGFR TKI (iressa at the standard 250 mg/day) as first line therapy. Specifically, they enrolled 30 patients who either had a poor performance status (3 or 4 on a scale of 0 to 5 where 0 is asymptomatic and 5 is dead: details here), or were 70 or older with a marginal performance status (2 -4) or 80 or older with any symptoms (1-4). It's worth noting that there are relatively few studies that include patients with a performance status of 2, and almost none that have included patients with a performance status of 3, who spend more than half of their day in bed and can't take care of many of their activities of daily living.

The exciting thing that they found was that these patients responded to gefitinib (response rate of 66%, right in line with the typical results for a population with an EGFR mutation) and had a much more favorable median survival, 18 months, than you'd expect for patients with a marginal or poor performance status (likely in the 2-6 month range). In the curves below, the yellow one shows the survival of a comparable group of Japanese frail patients who didn't have an EGFR mutation but also received iressa as first line therapy:

Poor PS EGFR Mut OS (Click to enlarge)

What was also impressive was that this very favorable response rate and median survival was associated with a very significant improvement in performance status for two thirds of the patients, as shown here (downward lines are favorable, since a lower performance status is more independent and less symptomatic):

PS improvement for EGFR Mutation patients on Gefitinib

It's important to highlight that his was a Japanese study and that we've seen major differences between Asian and North American populations in lung cancer outcomes, especially with regard to EGFR inhibitors. However, thus far it has really appeared that the differences are due primarily to differences in the molecular markers of tumors, so it's very likely that patients with the EGFR mutation positive tumors have a similar response to EGFR TKIs everywhere. Consequently, it seems likely that the previously noted unimpressive results with an EGFR inhibitor apply to the majority of poor performance status patients in North America, since only about 10% would be expected to carry an EGFR mutation. But for those who do have one, this study out of Japan would suggest that they have a high probability of a good response and improvement in symptoms, along with a prolonged survival, from early administration of an EGFR inhibitor.

The key appears to be in separating the major beneficiaries from the ones who won't benefit and may even be harmed from this approach. But this work provides the hope of treating certain elderly and/or very frail patients with an EGFR TKI and getting dramatic results.

Next Previous link

Previous PostNext Post

Related Content

Recent Live Events with the Global Resource for Advancing Cancer Education ~ View the Full OnDemand Lung Cancer OncTalk from February 2024  
Blood Cancer OncTalk 2023
In this first batch of the Q&A Session of Blood Cancer OncTalk, Drs. Aaron Goodman, Sridevi Rajeeve, Tycel Phillips, Alakrita Taneja, and Marco Ruiz come together to answer questions from the attendees at our Blood Cancer OncTalk 2023 live event.  To watch the complete playlist click here.
Blood Cancer OncTalk 2023
This is the third batch of videos from the Blood Cancer OncTalk playlist. In these videos, Dr. Alankrita Taneja defines Smoldering Multiple Myeloma (SMM) and discusses how it differs from Multiple Myeloma (MM), risk factors and treatments.   To watch the complete playlist click here.

Forum Discussions

Hi Oaktowngrrl,  Welcome to Grace.  I'm so sorry you're going through this.


 Finding a reputable dedicated thoracic surgeon for lung surgery might be difficult, as it is a complex and...

Hello Hello,  Just want to let you know I see your post and will respond more appropriately in the morning. 

Hi, I'm sorry for the delay.  It's OK to post with questions here, it's what the forums are for.  However, our expertise is not in diagnosing cancer but in knowledge of...

Recent Comments

Hi Oaktowngrrl,  Welcome to…
By JanineT GRACE … on
I can understand why you're…
By paulryan on
I'm so sorry to hear it.
By Andrian on

 I'm sure you're…
By JanineT GRACE … on